SecBot SecBot
PRESS-RELEASE ·Filed Nov 2, 2026

NBIX

Neurocrine Biosciences, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed14d 8h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The strong beat and raised INGREZZA guidance signal accelerating commercial momentum across three products. Watch for the December 15 R&D Day for pipeline updates on osavampator (MDD) and direclidine (schizophrenia) Phase 3 readouts, which could drive further upside.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

NBIX drug pipeline →

direclidine

● Neutral Named in this press release
Impact
Phase
Phase 3
Time to market
If Phase 3 trials succeed, a potential FDA submission could occur in 2028, with approval possible in 2029 at the earliest, assuming topline data reads out in 2027 and a standard ~12-month review cycle.
Next catalyst
None dated

What to watchThe next hard catalyst is Phase 3 topline data for direclidine in schizophrenia, expected in 2027 (timeline per Neurocrine's Q3 2026 earnings call on Nov 2, 2026). Positive data would validate direclidine as a potential competitor to the recently approved Cobenfy (KarXT) in the muscarinic agonist class; negative or mixed data would significantly hurt the stock given direclidine is one of Neurocrine's two late-stage pipeline assets.

Price Chart

Loading chart...

Executive Summary

Neurocrine Biosciences reported Q3 2026 total revenue of $1.123B, up 41% YoY, with net product sales exceeding $1B for the first time. Non-GAAP EPS of $3.29 beat the $2.75 consensus, and revenue of $1.123B beat the $1.04B consensus. INGREZZA net sales guidance was raised to $2.9B-$2.925B from $2.825B-$2.875B.

Key Financial Metrics

EPS (Adj.)
$3.29
est $2.75 · +19.6% · GAAP: $1.96
Revenue
$1.1B
est $1.0B · +8.0% · +41.2% YoY
Rating
strong beat
Guidance
$2.9B-$2.925B
raised

Key Facts

  • Total Q3 2026 revenue $1.123B, up 41% YoY from $795M
  • Non-GAAP EPS $3.29 vs consensus $2.75 (beat by 19.6%)
  • INGREZZA net sales $801M, up 17% YoY; guidance raised to $2.9B-$2.925B
  • CRENESSITY net sales $211M, up 115% YoY
  • VYKAT XR net sales $107M (first full quarter post-Soleno acquisition)
  • GAAP net income $206.5M vs $209.5M YoY; Non-GAAP net income $347M vs $222M YoY
  • Cash and marketable securities $790M at quarter end

Financial Impact

Revenue beat consensus by ~$83M (8%); EPS beat by $0.54 (19.6%); INGREZZA guidance raised by $75M at midpoint

revenueepsguidance

Segment Breakdown

SegmentRevenueGrowth
INGREZZA$801.0M+16.6%
CRENESSITY$211.0M+115.3%
VYKAT XR$107.0MNot reported

Risk Factors

  • Cash burn from R&D expansion and Soleno integration; cash dropped from $2.54B to $790M since year-end 2025
  • GAAP net income flat YoY despite revenue growth, due to higher operating expenses and $52M unrealized loss on equity investments
  • Dependence on INGREZZA for 71% of product sales; generic or competitive threats could erode the franchise

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (37 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302926995

Track record

30 reports on NBIX

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
  2. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  3. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  4. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  5. Nov 2, 202614d ago Press Release Bullish 6/10 Viewing No price data
  6. Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
  7. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
  8. Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
  9. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
  10. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
Showing 10 of 30

US Market Status

Market Closed · Opens in 7h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026